DNA encoding—candida albicans integrin-like protein

Details DNA encoding—candida albicans integrin-like protein DNA encoding—candida albicans integrin-like protein

1999-03-08

2002-02-12

Kaufman, Claire M. (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Fungi

C435S069100, C435S320100, C435S325000, C435S252300, C435S254200, C435S254210, C435S254220, C435S255400, C536S023740, C530S371000

Reexamination Certificate

active

06346411

ABSTRACT:

BACKGROUND OF THE INVENTION
Candida albicans
is the leading fungal pathogen in normal hosts and in patients with damaged immune systems. In normal hosts, disease caused by
C. albicans
ranges from mild, easily treated, superficial disease (e.g., thrush in newborn infants; paronychia in workers whose hands are immersed in water) to more severe, chronic or recurrent infections (e.g., candidal vaginitis). It is estimated that 5% of women of child-bearing age will suffer from recurrent candidal vaginitis (Hurley, “Trends in candidal vaginitis.”
Proc. R. Soc. Med
. 70 (Suppl. 4), 1-8 (1970), and that virtually every woman will experience at least one episode during her reproductive years. Vaginitis is particularly frequent in otherwise normal females with diabetes or a history of prolonged antibiotic or oral contraceptive use. While short-term topical therapy is effective in treating individual episodes of vaginitis, such agents do not prevent recurrences. Thus, even in the normal host, infection with
C. albicans
can occur at epithelial surfaces, and recurrences are not prevented by presently available therapies.
In immunocompromised hosts such as cancer patients, transplant patients, post-operative surgical patients, premature newborns, or HIV-infected people,
C. albicans
ranks as the leading fungal pathogen. In this population, disease ranges from aggressive local infections such as periodontitis, oral ulceration, or esophagitis in HIV-infected patients, to complex and potentially lethal infections of the bloodstream with subsequent dissemination to brain, eye, heart, liver, spleen, kidneys, or bone. Such grave prognoses require more toxic therapy, with attendant consequences from both the underlying infection and the treatment. Here again, the infection typically begins at an epithelial site, evades local defenses, and invades the bloodstream in the face of immunosuppression. Strategies to interrupt candidal adhesion therefore have broad applicability to the prevention of mild but recurrent disease in the normal host and to the reduction of substantial morbidity and mortality in the immunocompromised.
It is well recognized that
C. albicans
adheres to epithelial and endothelial cells in the human host, oftentimes by recognizing proteins of the extracellular matrix called ligands. These ligands include proteins such as fibronectin, vitronectin, fibrinogen, the C3 degradation fragment iC3b, or the shorter C3 degradation fragment C3d. Because recognition of all of these proteins except C3d is dependent upon the amino acid sequence ARGININE-GLYCINE-ASPARTIC ACID or R-G-D, these candidal adhesions are thought to operate like the vertebrate integrins and are called “integrin-like proteins” or “integrin analogs.”
Vertebrate integrins are composed of two subunits: an &agr;-subunit and a &bgr;-subunit. There are approximately 14 &agr; and 8 &bgr; subunits described to date in vertebrate cells. Using monoclonal or polyclonal antibodies to vertebrate integrins, several investigators have obtained evidence for integrin-like proteins in
C. albicans
: an &agr;M analog, an &agr; 5/&bgr;1 complex, or a &bgr;1 analog. Neither the &agr; 5/&bgr;1 complex nor the &bgr;1 analog has been isolated from
C. albicans
or from any other candidal species, and the responsible genes encoding these “integrin-like proteins” have not been identified.
SUMMARY OF THE INVENTION
The present invention provides an isolated and purified DNA molecule encoding a
Candida albicans
protein with integrin-like motifs that hybridizes to DNA complementary to DNA having SEQ ID NO:1 under the stringency conditions of hybridization in buffer containing 5×SSC, 5×Denhardt's, 0.5% SDS, 1 mg salmon sperm/25 mls of hybridization solution incubated at 65° C. overnight, followed by high stringency washing with 0.2×SSC/0.1% SDS at 65° C. Preferably, the present invention provides an isolated and purified DNA molecule encoding the
Candida albicans
protein with integrin-like motifs which has the amino acid sequence having SEQ ID NO:2. Preferably, the DNA is genomic DNA which has the nucleotide sequence shown in Table 1 (SEQ ID NO:1).
The present invention also provides a vector and a cell line transformed by an extrachromosomal plasmid containing non-native DNA encoding
Candida albicans
protein with integrin-like motifs (i.e.,
C. albicans
integrin-like protein), as described herein. The cell line preferably comprises
S. cerevisiae
. This cell line can be used in a method of delivering a gene product to a subject.
The present invention also provides a
Candida albicans
protein with integrin-like motifs comprising an I domain, two EF-hand divalent cation binding sites, a sequence sufficient to encode a transmembrane domain, an internal RGD tripeptide, and a carboxy-terminal sequence with a single tyrosine residue. As used herein, an “internal” RGD tripeptide means that the RGD sequence is in the Candida protein, not in the vertebrate proteins recognized by integrins. Preferably, the isolated and purified
C. albicans
integrin-like protein has an amino acid sequence which is SEQ ID NO:2. Also provided are isolated and purified peptides, such as those having an amino acid sequence selected from the group consisting of: YLS PTN NNN SKN VSD MDL HLQ NL (SEQ ID NO:4); DWK LED SND GDR EDN DDI SRF EK (SEQ ID NO:5); SKS ANT VRG DDD GLA SA (SEQ ID NO:6); DHL DSF DRS YNH TEQ SI (SEQ ID NO:7); and WIQ NLQ EII YRN RFR RQ (SEQ ID NO:8). The invention also provides a vaccine comprising the protein and peptides, either singly or together, described herein as well as an isolated and purified antibodies to the
C. albicans
integrin-like protein and peptides described herein.
The invention also provides a method of inhibiting adhesion of
Candida albicans
to cells (preferably epithelial cells, and more preferably human epithelial cells). The method includes contacting the
Candida albicans
with antibodies to the
Candida albicans
protein with integrin-like motifs (&agr;Int1p) or to fragments thereof as described herein.


REFERENCES:
patent: 4542020 (1985-09-01), Jackson et al.
patent: 4661454 (1987-04-01), Botstein et al.
patent: 4670382 (1987-06-01), Buckley et al.
patent: 4735901 (1988-04-01), Kurtz et al.
patent: 4806465 (1989-02-01), Buckley et al.
patent: 4835098 (1989-05-01), Orr et al.
patent: 5139936 (1992-08-01), Botstein et al.
patent: 5332660 (1994-07-01), Takeda et al.
Gale et al., Cloning and expression of a gene encoding an integrin-like protein inCandida albicans,Proc. Natl. Acad. Sci. USA, 93:357-361, Jan. 1996.*
GenBank Accession No. U35070, Accessed 5/98.*
S. Alaei et al., “Isolation and Biochemical Characterization of the iC3b Receptor ofCandida albicans”, Inf. Immun., 61(4), 1395-1399 (1993).
C.M. Bendel et al., “Distinct Mechanisms of Epithelial Adhesion forCandida albicansandCandida tropicalis”, J. Clin. Invest., 92,1840-1849 (1993).
C.M. Bendel et al., “Epithelial Adhesion in Yeast Species: Correlation with Surface Expression of the Integrin Analog”,J. Infec. Dis., 171,1660-1663 (1995).
R.A. Calderone et al., “Identification of C3d Receptors onCandida albicans”, Infect. Immun., 56(1), 252-258 (1988).
R.A. Calderone, “Molecular Interactions at the Interface ofCandida albicansand Host Cells”,Arch. of Med. Res., 24(3), 275-279 (1993).
R.A. Calderone, “Recognition betweenCandida albicansand host cells”,Trends Microbiol., 1,55-58 (1993).
R.W. Davis et al., “Rapid DNA Isolations for Enzymatic and Hybridization Analysis”,Methods Enzymol., 65404-411 (1980).
Frey et al, “Localization and Distribution of IC3B Binding Sites onCandida albicans,” 88thAnnual Meeting of the American Society for Microbiology,Miami Beach, FL, May 8-13, 1988, Abstract No. F-29.
C.A. Gale et al., “ACandida albicansGene with Integrin Motifs Induces Hyphal-Like Structures inS. Cerevisiae”, Pediatric Res., 37(4), Part II, Abstract No. 1030, and poster presentation (1995).
C. Gale et al., “Monoallelic Disruption of &agr;INT1 Reduces Antibody Binding, Adhesion, and Germ Tube Formation InC. Albicans”, Pediatric Res., 37(4), Part

Affiliated with

Also associated with

Rating

DNA encoding—candida albicans integrin-like protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA encoding—candida albicans integrin-like protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding—candida albicans integrin-like protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2959292